Energy-dispersive X-ray fluorescence determination of platinum in plasma, urine, and cerebrospinal fluid of patients administered cis-dichlorodiammineplatinum(II).
A method involving the use of an energy-dispersive X-ray fluorescence spectrometer was developed for assaying total platinum concentrations in body fluids of patients treated with the antitumor drug cis-dichlorodiammineplatinum(II). Sample preparation by this procedure is simple, consisting in adding an internal standard (Zr) to 1 ml of biological fluid or tissue homogenate, pipetting 20 microliter of the sample onto a Mylar sample holder, and drying. This produces a thin-film sample, which effectively eliminates absorption enhancement effects due to other elements in the specimen. Standard addition studies were found to be linear in the concentration range of interest (0.1-10.0 micrograms/ml), with correlation coefficients exceeding 0.99. Minimum detection limits range from 0.10 to 0.25 micrograms Pt per ml, depending on the body fluid, which is adequate for routine patient monitoring after normal chemotherapeutic doses of cis-dichlorodiammineplatinum(II). In preliminary studies with mammalian liver, standard addition experiments were found to be linear and the minimum detection limit was found to be 1.4 micrograms/g dry weight.
D001826:Body Fluids / Q000032:analysis*; D002945:Cisplatin / Q000378:metabolism*; D006801:Humans; D010984:Platinum / Q000032:analysis*; D013052:Spectrometry, X-Ray Emission; D013054:Spectrophotometry, Atomic
D010984:Platinum; D002945:Cisplatin